<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099176</url>
  </required_header>
  <id_info>
    <org_study_id>Ministry of Science</org_study_id>
    <nct_id>NCT01099176</nct_id>
  </id_info>
  <brief_title>Effects of Hypolipemic Treatment on Adipokines</brief_title>
  <official_title>The Effects of 90-day Monotherapies With Atorvastatin, Fenofibrate and Combined Therapy With Atorvastatin and Fenofibrate on Lipid Profile, Fasting Plasma Glucose, Proinflammatory Cytokines and Adipokines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Scientific Research and Information Technology, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Silesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is planned to show whether monotherapies or combined hypolipemic therapy influence
      the fasting plasma glucose, serum adipokines (leptin, adiponectin, resistin) and
      proinflammatory cytokines (interleukin-6, TNF alpha) during 30 and 90 day course.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adipokines</measure>
    <time_frame>Day 90</time_frame>
    <description>Serum concentration of leptin, adiponectin and resistin on Day 90 of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proinflammatory cytokines</measure>
    <time_frame>Day 30</time_frame>
    <description>Interleukin-6 and TNF alpha serum concentration on the Day 30 of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipokines</measure>
    <time_frame>Day 30</time_frame>
    <description>Serum concentration of leptin, adiponectin and resistin on Day 30 of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proinflammatory cytokines</measure>
    <time_frame>Day 90</time_frame>
    <description>Interleukin-6 and TNF alpha serum concentration on the Day 90 of the treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Impaired Fasting Glycemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg of Atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>267mg of Fenofibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate and atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg of Atorvastatin and 267mg of fenofibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic Lifestyle Change</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Therapeutic Lifestyle Change</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>To compare monotherapies and combined therapy with each other</intervention_name>
    <description>Each patient received two tablets per day. Time interval between pills - 12 hours.
In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_label>Fenofibrate and atorvastatin</arm_group_label>
    <arm_group_label>Therapeutic Lifestyle Change</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age (35-64yr)

          -  Primary hyperlipidemia (Total cholesterol &gt;200mg/dl, Triglycerides &gt;150mg/dl)

          -  Impaired fasting glycemia (glycemia 100-125mg/dl)

          -  For women:

          -  Menopause (&gt;12 months)

          -  Post hysterectomy

          -  Mechanical contraception

          -  Obtained informed consent

        Exclusion Criteria:

          -  Secondary hyperlipidemia

          -  Morbid obesity (BMI&gt;40kg/m2)

          -  Alcohol or drug abuse

          -  Acute or chronic inflammation

          -  Congestive Heart Failure (NYHA III or IV)

          -  Unstable Ischaemic Heart Disease

          -  Moderate or severe hypertension

          -  Cancer in less than 5 years

          -  Chronic kidney disease (stage III-V)

          -  Liver failure

          -  Diabetes

          -  Oral contraception

          -  Not compliant patient

          -  Laboratory results:

          -  alanine transferase (&gt;3xULN)

          -  creatine kinase (&gt;5xULN)

          -  haemoglobin (&lt;10/dl)

          -  PLT (&lt;100G/l)

          -  WBC (&lt;3,5G/l or &gt;10G/l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pharmacology</name>
      <address>
        <city>Katowice</city>
        <state>Śląskie</state>
        <zip>40-762</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>April 8, 2010</last_update_submitted>
  <last_update_submitted_qc>April 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Okopień Bogusław MD, PhD</name_title>
    <organization>Medical University of Silesia, Dept. of Pharmacology</organization>
  </responsible_party>
  <keyword>hyperlipidemia</keyword>
  <keyword>impaired fasting glycemia</keyword>
  <keyword>adipokines</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>fenofibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

